Skip to main content
Clinical Trials/NCT04315727
NCT04315727
Recruiting
N/A

Identification of the Genetic Causes of Rare Diseases With Negative Exome Findings

University Hospital Tuebingen1 site in 1 country100 target enrollmentFebruary 1, 2021

Overview

Phase
N/A
Intervention
Not specified
Conditions
Rare Diseases
Sponsor
University Hospital Tuebingen
Enrollment
100
Locations
1
Primary Endpoint
Identification of the molecular causes of unclear rare diseases
Status
Recruiting
Last Updated
2 years ago

Overview

Brief Summary

The GENOME + project will enroll patients (n = ca. 100) and their healthy parents with unclear molecular cause of the disease, suspected genetic cause of the disease and previous detailed molecular analysis like Whole Exome Sequencing (WES) did not lead to the identification of the disease causing mechanism. As well healthy parents of those affected for trio analysis (exception of one parent is not available for the study).

Detailed Description

In the GENOME+ study (monocentric, prospective, open-label diagnostic study), patients with molecularly undiagnosed diseases will diagnostically be analyzed by means of omics technologies or re-analyzed using existing datasets. The following questions will be leading the study: Primary: • Identification of the molecular causes of unclear rare diseases Secondary: * Improve number of diagnoses for patients with rare diseases * Further characterization of the identified putative disease causes * Increase number of patients receiving appropriate therapy after successful diagnosis. In addition, healthy parents of the subjects may be included in the study to perform parent-child (trio) analyses. In addition, phenotype and omics data will be shared within the University Hospital Tübingen, Germany and with external collaborators to improve the diagnostic rate of the patients included in the study. Storage of blood or tissue samples is not primary goal of this project, but may be necessary for further analyses.

Registry
clinicaltrials.gov
Start Date
February 1, 2021
End Date
December 2024
Last Updated
2 years ago
Study Type
Interventional
Study Design
Single Group
Sex
All

Investigators

Responsible Party
Sponsor

Eligibility Criteria

Inclusion Criteria

  • Unclear diagnosis
  • Suspected genetic cause of the disease
  • Previous detailed molecular analysis like Whole Exome Sequencing (WES) did not lead to the identification of the disease causing mechanism
  • Healthy parents of those affected for trio analysis (exception of one parent is not available for the study)

Exclusion Criteria

  • Missing informed consent of the patient and her/his parents

Outcomes

Primary Outcomes

Identification of the molecular causes of unclear rare diseases

Time Frame: Day 1

Number of molecular causes

Secondary Outcomes

  • Patients receiving appropriate therapy after successful diagnosis(Day 1)
  • Molecular characterization of putative disease causes(Day 1)
  • Diagnoses for patients with rare diseases(Day 1)

Study Sites (1)

Loading locations...

Similar Trials